Element Capital Management’s Regenxbio RGNX Stock Holding History

Element Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,165	Closed	-$217K	–	944
2018 Q4	$217K	Sell	5,165 -3,071	-37%	-$180K	0.01%	543
2018 Q3	$622K	Buy	8,236 +2,321	+39%	+$167K	0.01%	392
2018 Q2	$424K	Sell	5,915 -3,491	-37%	-$167K	0.01%	426
2018 Q1	$281K	Buy	+9,406	New	+$274K	0.01%	509

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Element Capital Management's RGNX Position: Q1 2019 in Review

Element Capital Management sold out of Regenxbio (RGNX) in Q1 2019, closing a stake of 5,165 shares — an estimated $217K sold.

Element Capital Management first reported a position in RGNX in Q1 2018 and held it in 4 quarters. The position peaked at $622K in Q3 2018. 211 funds tracked by Wall St. Rank hold RGNX as of Q1 2019.

Element Capital Management reported no remaining Regenxbio position as of Q1 2019 after selling out during the quarter.
Element Capital Management sold 5,165 Regenxbio shares in Q1 2019, an estimated $217K.
Element Capital Management first reported a position in Regenxbio in Q1 2018 and held it in 4 quarters.
Element Capital Management's Regenxbio position peaked at $622K in Q3 2018.
211 funds tracked by Wall St. Rank held Regenxbio as of Q1 2019.

Based on Element Capital Management's 13F filing for Q1 2019, filed 13 May 2019.